Endo Axiom
A clinical-stage biotechnology company developing investigational oral insulin using enzyme-responsive, liver-targeting nanotechnology. Phase 1a first-in-human dosing has commenced.
How the company was formed, and what it is building.
Endo Axiom is a clinical-stage biotechnology company developing an investigational oral insulin programme. Its enzyme-responsive, liver-targeting nanotechnology is designed to protect insulin through the gastrointestinal tract and deliver it through the portal circulation to the liver.
The programme builds on more than 20 years of research spanning the University of Sydney, Sydney Local Health District and the ANZAC Research Institute, led by Professor Victoria Cogger, Professor David Le Couteur AO and A/Prof Nicholas Hunt. Proto Axiom partnered with the inventors in April 2023 to form the company, license the underlying IP from the University of Sydney, establish management and fund development.
In September 2026, Endo Axiom commenced dosing in its Phase 1a first-in-human clinical trial, becoming the first company incubated by Proto Axiom to reach human trials. The study is conducted at CMAX Clinical Research in Adelaide and managed by Datapharm Australia.
- Founded
- 2023
- Origin
- University of Sydney / ANZAC Research Institute
- Sector
- Therapeutics
- Modality
- Oral insulin · Nanotechnology
Founders and key team.
Where the programme is now, and what comes next.
- Now
- Phase 1a first-in-human clinical trial under way. Dosing commenced in September 2026 at CMAX Clinical Research in Adelaide, with Datapharm Australia managing the study.